2-异丁基-6-甲氧基异烟酸 | 1011347-26-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-异丁基-6-甲氧基异烟酸
• 英文名称: 2-isobutyl-6-methoxyisonicotinic acid
• 英文别名: 2-methoxy-6-(2-methylpropyl)pyridine-4-carboxylic acid
• CAS: 1011347-26-4
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: ZCXGDYSTVJHTDA-UHFFFAOYSA-N

物化性质

• 沸点：
  385.6±42.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-异丁基-6-甲氧基异烟酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 8.08h， 生成 2-ethyl-4-(5-(2-isobutyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenol
  参考文献：
  名称：

  Novel S1P1 receptor agonists – Part 5: From amino-to alkoxy-pyridines

  摘要：

  In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P(1) receptor agonist. More detailed studies revealed that this compound is phototoxic in vitro. As a result of efforts aiming at eliminating this undesired property, a series of alkoxy substituted pyridine derivatives was discovered. The photo irritancy factor (PIF) of these alkoxy pyridines was significantly lower than the one of aminopyridine 1 and most compounds were not phototoxic. Focused SAR studies showed, that 2-, 3-, and 4-pyridine derivatives delivered highly potent S1P(1) receptor agonists. While the 2-pyridines were clearly more selective against S1PR(3), the corresponding 3- or 4 pyridine analogues showed significantly longer oral half-lives and as a consequence longer pharmacological duration of action after oral administration. One of the best compounds, cyclopentoxy-pyridine 45b lacked phototoxicity, showed EC50 values of 0.7 and 140 nM on S1PR(1) and S1PR(3), respectively, and maximally reduced the blood lymphocyte count for at least 24 h after oral administration of 10 mg/kg to Wistar rats. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.03.020
• 作为产物：
  描述：

  2-Methoxy-6-(2-methylprop-1-enyl)pyridine-4-carboxylic acid 在 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 反应 16.0h， 生成 2-异丁基-6-甲氧基异烟酸
  参考文献：
  名称：

  [EN] THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING
  [FR] MODULATEURS THIADIAZOLE DE S1P ET PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  该发明涉及以下结构的化合物：其中这些变量在此有定义，以及制备和使用这些化合物作为S1P1和/或S1P5的激动剂的方法，例如用于治疗自身免疫疾病。

  公开号：

  WO2017004609A1

文献信息

• PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS
  申请人：Bolli Martin

  公开号：US20110212998A1

  公开（公告）日：2011-09-01

  The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

  本发明涉及式（D）的新吡啶衍生物、它们的制备方法以及它们作为药物活性化合物的用途。所述化合物特别是作为免疫调节剂发挥作用。式（I）中，A代表，其他取代基如权利要求中所定义。
• [EN] PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIDINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009024905A1

  公开（公告）日：2009-02-26

  The invention relates to novel pyridine derivatives of formula (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.

  该发明涉及公式（I）的新型吡啶衍生物，其制备以及作为药用活性化合物的用途。所述化合物特别作为免疫调节剂。公式（I）中A代表，其他取代基如索引中定义。
• Pyridin-4-yl derivatives as immunomodulating agents
  申请人：Bolli Martin

  公开号：US20100063108A1

  公开（公告）日：2010-03-11

  The invention relates to pyridine derivatives of Formula (I) wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  该发明涉及公式（I）中的吡啶衍生物，其中A、R1、R2、R3、R4、R5和R6如描述中所述，它们的制备以及它们作为药用活性化合物的用途。所述化合物特别作为免疫调节剂。
• PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2069336B1

  公开（公告）日：2012-12-26
• US8580824B2
  申请人：——

  公开号：US8580824B2

  公开（公告）日：2013-11-12